Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX4204 + Erlotinib in Advanced NSCLC
NCT02991651Phase 1Terminated
- Sponsor
- Io Therapeutics, Inc.
- Start
- Dec 2016
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of irx4204 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Io Therapeutics, Inc. Primary endpoint: Safety of co-administration of IRX4204 + erlotinib at 30 days. Started Dec 2016; status: terminated.
02
Drugs
irx4204
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02991651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991651.